



NDA 208383/S-007

## SUPPLEMENT APPROVAL

Portola  
Attention: Susanne Fors  
Senior Vice President, Regulatory Affairs  
270 East Grand Avenue  
South San Francisco, CA 94080

Dear Mr. Fors:

Please refer to your supplemental new drug application (sNDA) dated May 14, 2020, received May 14, 2020, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for BEVYXXA (betrixaban).

On April 17, 2020, FDA sent a supplement request to add a new Section 5.5: "Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome".

This "Changes Being Effected" supplemental new drug application provides for adding a new Section 5.5 "Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome as requested by the FDA.

### **APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Alice Kacuba at 301-796-1381 or at [alice.kacuba@fda.hhs.gov](mailto:alice.kacuba@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Rosanna Setse, MD, PhD  
(Acting) Deputy Director for Safety  
Division of Nonmalignant Hematology  
Office of Cardiology, Hematology, Endocrinology,  
and Nephrology  
Center for Drug Evaluation and Research

#### ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information

---

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

ROSANNA W SETSE  
08/24/2020 03:54:00 PM